Curacle Co. Ltd.
curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company's products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition… Read more
Curacle Co. Ltd. (365270) - Net Assets
Latest net assets as of September 2025: ₩38.92 Billion KRW
Based on the latest financial reports, Curacle Co. Ltd. (365270) has net assets worth ₩38.92 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩55.59 Billion) and total liabilities (₩16.67 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩38.92 Billion |
| % of Total Assets | 70.02% |
| Annual Growth Rate | N/A |
| 5-Year Change | 345.31% |
| 10-Year Change | N/A |
| Growth Volatility | 318.71 |
Curacle Co. Ltd. - Net Assets Trend (2018–2024)
This chart illustrates how Curacle Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Curacle Co. Ltd. (2018–2024)
The table below shows the annual net assets of Curacle Co. Ltd. from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩29.95 Billion | -28.45% |
| 2023-12-31 | ₩41.86 Billion | -9.33% |
| 2022-12-31 | ₩46.17 Billion | -16.08% |
| 2021-12-31 | ₩55.02 Billion | +717.92% |
| 2020-12-31 | ₩6.73 Billion | +145.56% |
| 2019-12-31 | ₩-14.76 Billion | -778.11% |
| 2018-12-31 | ₩-1.68 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Curacle Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8742864832000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩121.20 Billion | 404.63% |
| Total Equity | ₩29.95 Billion | 100.00% |
Curacle Co. Ltd. Competitors by Market Cap
The table below lists competitors of Curacle Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CRAWFORD + CO. B DL 1
F:CWK
|
$177.72 Million |
|
EREX CO. LTD
F:6HF
|
$177.75 Million |
|
Pilani Investment and Industries Corporation Limited
NSE:PILANIINVS
|
$177.83 Million |
|
Trifork Holding AG
CO:TRIFOR
|
$177.83 Million |
|
Editas Medicine Inc
NASDAQ:EDIT
|
$177.67 Million |
|
Chinhung International Inc
KO:002785
|
$177.63 Million |
|
Evli Pankki Oyj
HE:EVLI
|
$177.59 Million |
|
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd
SHE:301126
|
$177.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Curacle Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 41,863,176,440 to 29,953,335,480, a change of -11,909,840,960 (-28.4%).
- Net loss of 14,886,473,150 reduced equity.
- Share repurchases of 114,540,800 reduced equity.
- New share issuances of 114,540,800 increased equity.
- Other factors increased equity by 2,976,632,190.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-14.89 Billion | -49.7% |
| Share Repurchases | ₩114.54 Million | -0.38% |
| Share Issuances | ₩114.54 Million | +0.38% |
| Other Changes | ₩2.98 Billion | +9.94% |
| Total Change | ₩- | -28.45% |
Book Value vs Market Value Analysis
This analysis compares Curacle Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.98x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | ₩-125.89 | ₩18320.00 | x |
| 2019-12-31 | ₩-1105.48 | ₩18320.00 | x |
| 2020-12-31 | ₩441.56 | ₩18320.00 | x |
| 2021-12-31 | ₩3524.14 | ₩18320.00 | x |
| 2022-12-31 | ₩3334.60 | ₩18320.00 | x |
| 2023-12-31 | ₩2568.60 | ₩18320.00 | x |
| 2024-12-31 | ₩1835.38 | ₩18320.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Curacle Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -49.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -911.85%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.98x
- Recent ROE (-49.70%) is above the historical average (-77.08%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-2.66 Billion |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-12.51 Billion |
| 2020 | -425.33% | 0.00% | 0.00x | 1.89x | ₩-29.28 Billion |
| 2021 | -12.14% | -106.76% | 0.10x | 1.19x | ₩-12.18 Billion |
| 2022 | -24.70% | -318.34% | 0.06x | 1.21x | ₩-16.02 Billion |
| 2023 | -27.68% | -112.54% | 0.15x | 1.67x | ₩-15.77 Billion |
| 2024 | -49.70% | -911.85% | 0.03x | 1.98x | ₩-17.88 Billion |
Industry Comparison
This section compares Curacle Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $259,224,420,269
- Average return on equity (ROE) among peers: -0.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Curacle Co. Ltd. (365270) | ₩38.92 Billion | 0.00% | 0.43x | $177.67 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.37 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $229.70 Million |
| Green Cross Holdings Preference Shares (005257) | $1.88 Trillion | -2.88% | 0.99x | $409.02 Million |
| Pharmicell (005690) | $76.66 Billion | 10.78% | 0.43x | $453.92 Million |
| GeneOne Life Science Inc (011000) | $23.71 Billion | -35.27% | 0.34x | $52.94 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $19.73 Billion | 2.26% | 0.29x | $14.76 Million |
| Seoulin Bioscience Co.Ltd (038070) | $59.92 Billion | 8.17% | 0.31x | $27.84 Million |
| Hyundai Bioscience Co. Ltd (048410) | $60.94 Billion | 0.00% | 2.69x | $964.67 Million |
| iNtRON Biotechnology Inc (048530) | $49.15 Billion | -1.24% | 0.21x | $83.99 Million |
| Synergy Innovation Co. Ltd (048870) | $71.09 Billion | 0.00% | 0.77x | $77.78 Million |